BRAF and prostate carcinoma: Since activated BRAF is one of the most potent activators of MAP kinase signaling and BRAFV600E mutation itself has been described in a subset of human prostate cancers[25], this iBRAF* model represents a potentially useful in vivo system in which to address the role of MAP kinase activation in prostate cancer genesis and progression.